Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc V.VER.H

Alternate Symbol(s):  VRSEF

Verisante Technology, Inc. is a Canada-based company. The Company does not operate any active business other than to identify and complete a reverse takeover (RTO) with a company in one of its target sectors that demonstrates significant growth potential and/or value creation opportunities for shareholders. The Company may pursue a target in any industry, it intends to focus its search on companies that meet its acquisition target characteristics within the life sciences sectors.


TSXV:VER.H - Post by User

Bullboard Posts
Post by herbaciouson May 03, 2011 9:07pm
330 Views
Post# 18525987

VANCOUVER BUSINESS REPORTS

VANCOUVER BUSINESS REPORTS

Business in Vancouver Reports on Verisante

May 3, 2011

Business in Vancouver reporter Nelson Bennett writes:

The Canadian Institutes of Health Research (CIHR) has approved a $292,000 grant to the BC Cancer Agency, which in turn will use the money to help the company finalize testing and optimization of its Verisante Aura device. As part of the funding arrangement, Verisante will contribute $303,800.

Thomas Braun, president and CEO of Verisante, said the grant not only helps the company financially, it also helps lend credibility to its technology.

“Some people think that it’s quite important in terms of validating the technology,” he told Business in Vancouver.

The Verisante Aura uses a pen-sized spectroscope that scans the skin and can detect cancer bio-markers. A positive reading tells the physician the patient should have a biopsy. Negative readings would mean many costly biopsies could be avoided.

Read the entire article on our website at:
https://verisante.com/news/media/

do your own due diligence

herb

Bullboard Posts